abstract |
The efficiency of dextran sulfate treatment is determined based on differences between the amount of biomarkers determined in a second biological sample taken from the patient following dextran sulfate administration and in a first biological sample taken from the patient prior to dextran sulfate administration. The biomarkers are selected from 6 groups consisting of PFA4 and VAV3 (group 1); TNFSF15, IL-17B, TSLP and CRH (group 2); FGF1 and KITLG (group 3); BDNF, NOG and HBEGF (group 4); AFP, ATP2A3, SLC29A1, SLC40A1 and TTR (group 5); and SLC1A4, SLC7A11, SLC16A7, LDLR and ATP8A1 (group 6). |